Antibody Solutions

Antibody Solutions Secures Grant for Challenging Diagnostic Initiative

Retrieved on:

Thursday, April 4, 2024

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.

Key Points:

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.
The end result is that those RDTs are unable to differentiate between different strains of malaria,” explained John Kenney, PhD, co-founder and president of Antibody Solutions.
”
Antibody Solutions has already begun work to identify these new antibody reagents by harnessing Cellestive, its antibody discovery platform, that includes multiple discovery pathways such as hybridoma library, primary B-cell screening, and guided next-generation sequencing (NGS).
The grant from the foundation will also allow Antibody Solutions to work with industry experts in both public health and the development and deployment of healthcare solutions in low- and middle-income (LMIC) settings, ensuring that these reagents will be widely available.

North America Leads the Way: The Regional Powerhouse in the Global Antibody Discovery Services and Platforms Market - ResearchAndMarkets.com

Retrieved on:

Tuesday, October 24, 2023

Due to the complexities associated with discovering such antibodies, many firms are licensing and utilizing specialized antibody discovery platforms and technologies, driving the growth of the antibody discovery services and platforms market.

Key Points:

Due to the complexities associated with discovering such antibodies, many firms are licensing and utilizing specialized antibody discovery platforms and technologies, driving the growth of the antibody discovery services and platforms market.
The global market size for antibody discovery services and platforms is projected to grow at an annualized CAGR of 11.0% during the forecast period.
Key players in the antibody discovery services and platforms market include Ablexis, Antibody Solutions, ChemPartner, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, and more.
In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary after acquiring Abveris, an antibody discovery CRO, in 2022.

Antibody Drug Discovery: From Target Validation to Candidate Selection, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Tuesday, August 15, 2023

Drug discovery, Therapy, Safety, Antibody Solutions, Doctor of Philosophy, Vaccine

TORONTO, Aug. 15, 2023 /PRNewswire-PRWeb/ -- This webinar will provide an overview of the antibody discovery process highlighting the critical steps involved in developing effective antibody-based therapeutics. The goal is to guide the audience through the different stages of antibody drug discovery, shedding light on the latest advancements, methodologies and challenges encountered along the way. In addition, the webinar will cover Benchling's Antibody Solution Accelerator, a set of ready-to-use configurations necessary to capture the process of drug discovery.

Key Points:

The audience will be guided through the different stages of antibody drug discovery, shedding light on the latest advancements, methodologies and challenges encountered along the way.
Register now to learn best practices for target identification, screening, lead selection and in vivo safety and efficacy.
In addition, the webinar will cover Benchling 's Antibody Solution Accelerator, a set of ready-to-use configurations necessary to capture the process of drug discovery.
Throughout the webinar, attendees will gain valuable insights into how Benchling's Antibody Solution Accelerator supports the critical elements of antibody discovery, ensuring a more streamlined and successful drug development process.

Apexigen to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Retrieved on:

Monday, August 2, 2021

Life sciences, Biology, Health sciences, Biotechnology, Immunology, Monoclonal antibody, Biopharmaceutical, Antibody, Antibody Solutions

SAN CARLOS, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Key Points:

SAN CARLOS, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.
Sotigalimab and Apexigens other programs were discovered using Apexigens proprietary APXiMAB discovery platform.
This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies.
Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees.

Apexigen to Participate in Upcoming Investor Conferences

Retrieved on:

Thursday, July 8, 2021

Life sciences, Medical specialties, Biology, Immunology, Biotechnology, Immune system, Monoclonal antibody, Antibody, Cancer immunotherapy, Biopharmaceutical, Sutro Biopharma, Antibody Solutions

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patients immune system to combat and eradicate cancer.

Key Points:

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patients immune system to combat and eradicate cancer.
Sotigalimab and Apexigens other programs were discovered using Apexigens proprietary APXiMAB discovery platform.
This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies.
Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees.

Proteintech Group Celebrates 20-Year Anniversary

Retrieved on:

Tuesday, June 15, 2021

Health, Genetics, Other Science, General Health, Research, Science, Biotechnology, Biology, Branches of biology, Immunology, Biochemistry, Antibodies, Glycoproteins, Reagent, Biotechnology, Antibody Solutions, Affimer

Proteintech Group, a leading manufacturer of antibodies and related products, is celebrating the 20th anniversary of its founding.

Key Points:

Proteintech Group, a leading manufacturer of antibodies and related products, is celebrating the 20th anniversary of its founding.
With antibodies for two-thirds of the human genome, Proteintech has the largest self-manufactured target coverage of all antibody companies.
These high-performance recombinant reagents will help Proteintech address opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.
With locations in the US, UK, Germany, Singapore, China and Japan, Proteintech is able to provide fast delivery around the world.

AbSci Announces Acquisition of Target Discovery Company Totient

Retrieved on:

Monday, June 14, 2021

Branches of biology, Biology, Biochemistry, Immunology, Immune system, Glycoproteins, Biotechnology, Antibody, Antigen, Antibody Solutions

VANCOUVER, Wash., June 14, 2021 /PRNewswire/ --AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the acquisition of Totient, a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets.

Key Points:

VANCOUVER, Wash., June 14, 2021 /PRNewswire/ --AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the acquisition of Totient, a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets.
This acquisition adds antibody and target discovery technology to AbSci's platform for therapeutic protein design and biomanufacturing optimization.
To date Totient has reconstructed more than 4,500 antibodies from over 50,000 patients and has de-orphaned a collection of promising antibodies by identifying and validating their target antigens.
AbSci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics.

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

Retrieved on:

Wednesday, June 2, 2021

Contract manufacturing organization, Pharmaceutical industry, Antibody Solutions, GenScript Biotech, Life sciences, Biology

Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.

Key Points:

Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.
"We are excited to enter into this new relationship with Ligand, which has one of the best antibody discovery platforms in the world," said Brian Min, Ph.D., CEO of GenScript ProBio.
GenScript ProBio, already a qualified OmniAb contract research organization (CRO) for antibody discovery services, is now the second contract development and manufacturing organization (CDMO) in China to secure a global license to the transgenic rodent technology of the OmniAb platform.
With more than 16 years of experience in custom antibody services for various targets, GenScript ProBio provides a range of immunization methods.

Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

Retrieved on:

Thursday, May 27, 2021

Though the vaccine rollout is underway, antibody treatments remain an important therapeutic measure to reduce the number of hospitalizations and deaths due to COVID-19."

Key Points:

Though the vaccine rollout is underway, antibody treatments remain an important therapeutic measure to reduce the number of hospitalizations and deaths due to COVID-19."
Vir and GSK are evaluating sotrovimab in an extensive ongoing clinical development program.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.
Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.

Genovac Antibody Discovery Launches in NDSU Research and Technology Park

Retrieved on:

Monday, April 26, 2021

Life sciences, Biology, Immunology, Biotechnology, Antibody, Glycoproteins, Biopharmaceutical, Antibody Solutions, Symphogen

b'Genovac Antibody Discovery has launched in the United States following a management buyout of an antibody discovery business unit owned by Aldevron, a U.S.-based contract manufacturing organization.

Key Points:

b'Genovac Antibody Discovery has launched in the United States following a management buyout of an antibody discovery business unit owned by Aldevron, a U.S.-based contract manufacturing organization.
The company\xe2\x80\x99s core technology, genetic immunization, enables rapid antibody discovery against biopharma\xe2\x80\x99s most challenging targets.\nThe company has served the biopharmaceutical industry for more than 20 years and has completed over 3,500 projects, providing antibodies that have been developed into clinical and commercial drugs.
The platform enables Genovac to make DNA for genetic immunization in one week, compared to the months it would take using the traditional, protein-based method for antibody discovery.
All are rich sources for antibodies that can be developed into human therapeutics.\nWalters was Aldevron\xe2\x80\x99s chief financial officer prior to leading its Antibody Discovery Group.